Skip to main content

Clinical Trial Search Results

Clinical Trial Search Results

Showing 1-9 out of 371 results.
NCT04128423

A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

Icon for trial | AMV564-301 A Phase 1 Dose Escalation With Expansion Study to Evaluate the Safety, Tolerability, Pharmacokinetics, and Efficacy of AMV564 Alone and in Combination with Pembrolizumab in Subjects with Advanced Solid Tumors

This study is currently enrolling.

The purpose of this clinical research study is to learn more about the safety of AMV564, and to learn how AMV564 affects your cancer-specific cells and other blood cells. In addition, the study will look at how long AMV564 can ...

NCT04736706

An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-line Treatment in Participants with Advanced Clear Cell Renal Cell Carcinoma (ccRCC)

Icon for trial | MK-6482-012 An Open-label, Randomized Phase 3 Study to Evaluate Efficacy and Safety of Pembrolizumab (MK-3475) in Combination with MK-6482 and Lenvatinib (MK-7902), or MK-1308A in Combination with Lenvatinib, versus Pembrolizumab and Lenvatinib, as First-

This study is currently enrolling.

This trial is testing 3 combination therapies in people with a specific type of kidney cancer called advanced clear cell renal cell carcinoma (ccRCC). These 3 therapies are: (1) HIF triplet: pembrolizumab plus MK-6482 (belzutif ...

NCT04464785

CentriMag Failure-to-Wean Post Approval Study

Icon for trial | ABT-CIP-10336 CentriMag Failure-to-Wean Post Approval Study

This study is currently enrolling.

You are being invited by your doctor to take part in this research study evaluating the post-market performance of the FDA-approved CentriMag Circulatory Support System because your doctor has determined that this device could ...

NCT03556020

PHASEBIO - A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous Injections of a Sustained-Release VIP Analogue, PB1046, in Adult Subjects with Symptomatic Pulmonary Arterial Hypertension

Icon for trial | PB1046-PT-CL-004 PHASEBIO - A Randomized, Double-Blind, Parallel Group, Phase 2 Study to Assess the Safety, Tolerability, and Efficacy of Once Weekly Subcutaneous Injections of a Sustained-Release VIP Analogue, PB1046, in Adult Subjects with Symptomatic P

This study is currently enrolling.

You are being asked to participate in this study because your doctors have determined that you have PAH. PAH greatly increases the workload on the right side of the heart and over time may lead to dizziness, difficulty breathi ...